The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma

Launched by WUHAN AMMUNITION LIFE-TECH CO., LTD · Aug 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new test called IUrisure to see how well it can detect the return of a specific type of cancer called urothelial carcinoma. Urothelial carcinoma affects the bladder and other parts of the urinary system. The trial aims to find out if the IUrisure test is as effective as the traditional method of checking for cancer recurrence, which involves a procedure called cystoscopy and examining tissue samples.

To participate in this study, patients should be between the ages of 65 and 74 and have either a confirmed diagnosis of urothelial carcinoma or a strong suspicion of its return. They must be eligible for certain types of surgeries related to their condition. Participants will need to agree to join the study and sign a consent form. If you or someone you know qualifies, this trial offers a chance to help improve cancer detection methods for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with high suspicion/confirmed urothelial carcinoma by CT, CTU, MR and other imaging examinations and meet the indications for surgery, including TURbt, partial cystectomy, radical nephroperectomy and kidney-sparing surgery;
• • 2. Patients with highly suspected/confirmed recurrence of urothelial carcinoma who meet the indications for surgery, including TURbt, partial cystectomy, radical nephroperectomy and kidney-sparing surgery;
• • 3. The patient agrees to participate in this study and has signed the informed consent form.
• Exclusion Criteria:
• • (1) Patients with urothelial carcinoma combined with other malignant tumors; (2) Patients with a history of other non-urothelial carcinoma cancers; (3) Samples that are not urothelial carcinoma in surgical pathology; (4) Samples of Ta/low-grade urothelial carcinoma shown by surgical pathology.